Although both cabozantinib and regorafenib have antiangiogenic properties via VEGFR2 and TIE2 inhibition and share similar kinase target profiles, regorafenib does not inhibit MET, which could explain the observed differences in treatment effects of cabozantinib and regorafenib in CRC cells. The gene discussed is MET; the disease is colorectal carcinoma.